RhumbLine Advisers’s NanoViricides NNVC Stock Holding History

RhumbLine Advisers’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,873	Closed	-$84K	–	3065
2015 Q1	$84K	Buy	1,873 +405	+28%	+$21.6K	﹤0.01%	2976
2014 Q4	$80K	Buy	1,468 +48	+3%	+$3.18K	﹤0.01%	2976
2014 Q3	$85K	Buy	1,420 +103	+8%	+$8.09K	﹤0.01%	2943
2014 Q2	$111K	Buy	+1,317	New	+$93.5K	﹤0.01%	2963

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

RhumbLine Advisers's NNVC Position: Q2 2015 in Review

RhumbLine Advisers sold out of NanoViricides (NNVC) in Q2 2015, closing a stake of 1,873 shares — an estimated $84K sold.

RhumbLine Advisers first reported a position in NNVC in Q2 2014 and held it in 4 quarters. The position peaked at $111K in Q2 2014. 48 funds tracked by Wall St. Rank hold NNVC as of Q2 2015.

RhumbLine Advisers reported no remaining NanoViricides position as of Q2 2015 after selling out during the quarter.
RhumbLine Advisers sold 1,873 NanoViricides shares in Q2 2015, an estimated $84K.
RhumbLine Advisers first reported a position in NanoViricides in Q2 2014 and held it in 4 quarters.
RhumbLine Advisers's NanoViricides position peaked at $111K in Q2 2014.
48 funds tracked by Wall St. Rank held NanoViricides as of Q2 2015.

Based on RhumbLine Advisers's 13F filing for Q2 2015, filed 4 Aug 2015.